Skip to main content

New Posts

House Passes Bill Protecting Students With Asthma and Allergies, Moves to Senate for Vote

On Sept. 29, 2020, the House of Representatives passed the School-Based Allergies and Asthma Management Program Act (H.R. 2468) . If passed by the Senate and signed into law by the president, this bill will help millions of U.S. school children with asthma and food allergies. This bill includes many of the policy recommendations from the Asthma and Allergy Foundation’s (AAFA) State Honor Roll for all public elementary and secondary schools. It would encourage states to put into place:...

Causes of Fall Allergy Symptoms and What You Can Do About Them

Ah, fall! Time for cozy jackets, colorful leaves, pumpkin spice lattes and … allergy medicine? If you’ve noticed the change in season also triggers allergy and asthma symptoms, you’re not alone. Just like spring, fall is a time when many people are seeking relief from their seasonal allergies . Common symptoms of seasonal allergies include: Runny nose and mucus Sneezing Itchy nose, eyes, ears and mouth Stuffy nose (nasal congestion) Red and watery eyes Swelling around the eyes Do You Live in...

Teva Announces Two More Digital Inhalers for Asthma - AirDuo® Digihaler® and ArmonAir® Digihaler®

Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder and ArmonAir® Digihaler® (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma. AirDuo® Digihaler® is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older.

Trelegy Ellipta Inhaler Is Now Approved for Asthma Treatment

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.